Thiazolidinediones (TZDs) comprise a class of hypoglycemic drugs which reduce insulin resistance in peripheral tissues. Evidences indicate that TZDs hypoglycemic effects is peroxisome proliferator-activated receptors (PPARs) mediated, on its gamma, alpha and/or beta/delta isoforms. Initially, three TZDs were approved to clinical use: troglitazone, rosiglitazone and pioglitazone. Recently, these drugs have been associated to important side effects, such as hepatotoxicity, cardiovascular risk and lipid profile alterations. Thus, the search for new thiazolidine compounds, which could share beneficial effects and minimize side effects were propelled. As a result, many new compounds have been developed and many others are on pre-clinical and clinical trials.Preliminary in vivo data showed that a new thiazolidine compound - GQ-11 - modulates cytokines with important role in inflammation processes turning it into a promising alternative on healing/ tissue repair therapy and treatment. In addition, it could be a special alternative at impaired metabolisms, such as in wound healing on diabetic patients and on vascular surgery, acting as a preventive agent of complications from an impaired inflammatory metabolism. In this sense, we propose deeply investigate and elucidate signaling pathways of inflammatory process and wound/tissue healing, allowing to understand GQ-11 action mechanisms and its benefits in two animal models: insulin resistance and visceral ischemia.
News published in Agência FAPESP Newsletter about the scholarship: